Bo Jesper Hansen
Chairman at Innoventa Medica ApS
Network origin in Bo Jesper Hansen first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 46 | |
University of Copenhagen
29
| College/University | Other Consumer Services | 29 |
| Public Company | Financial Conglomerates | 22 | |
| Public Company | Pharmaceuticals: Major | 21 | |
| Subsidiary | Pharmaceuticals: Major | 19 | |
Wellington Partners GmbH
 Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto.
17
| Private Company | Investment Managers | 17 |
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden.
15
| Extinct | Miscellaneous Commercial Services | 15 |
14
| Subsidiary | Biotechnology | 14 |
Swedish Orphan International Holding AB
 Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets.
14
| Extinct | Pharmaceuticals: Major | 14 |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna.
14
| Operating Division | Investment Managers | 14 |
| Public Company | Biotechnology | 12 | |
| Extinct | Pharmaceuticals: Major | 12 | |
Reapplix A/S
 Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark.
11
| Holding Company | Medical Distributors | 11 |
Azanta A/S
 Azanta A/S Pharmaceuticals: MajorHealth Technology Azanta A/S develops pharmaceutical drugs for medical treatments in women´s health, oncology and addiction medicine. Its products include Angusta, which helps in cervical ripening and induction of labor. The firm also develops drugs for the treatment of head and neck cancer patients undergoing with radiotherapy. The company was founded by Claus Juan Møller-San Pedro and Jan Andersen in 1994 and is headquartered in Valby, Denmark.
11
| Subsidiary | Pharmaceuticals: Major | 11 |
Novagali Pharma SA
 Novagali Pharma SA Pharmaceuticals: MajorHealth Technology Novagali Pharma SA specializes in research, development and marketing of ophthalmic drugs. Their product pipeline includes products at various stages of development, which address diseases encountered at the three different segment levels of the eye which are surface, anterior and posterior segments. Some of these diseases are dry eye, allergy, glaucoma and retinopathies. Their formulations are based on their technology platforms Novasorb and Eyeject, which optimize bioavailability of drugs as well as safety and comfort for the patient. The company was founded on August 8, 2000 and is headquartered in Evry, France.
9
| Extinct | Pharmaceuticals: Major | 9 |
| Public Company | Pharmaceuticals: Major | 6 | |
Gambro AB
 Gambro AB Medical SpecialtiesHealth Technology Gambro AB engages in the development and manufacturing of dialysis equipment and blood purification products. It provides products and therapies for kidney and liver dialysis, myeloma kidney therapy, and other extracorporeal therapies for chronic and acute patients. The firm offers products for hemodialysis, acute care, myeloma kidney therapy, and vascular access and water systems. The company was founded by Holger Crafoord in 1964 and is headquartered in Lund, Sweden.
4
| Subsidiary | Medical Specialties | 4 |
Amylon Therapeutics BV
 Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands.
2
| Holding Company | Pharmaceuticals: Major | 2 |
Swedish Orphan Biovitrum International AB
 Swedish Orphan Biovitrum International AB Pharmaceuticals: MajorHealth Technology Swedish Orphan Biovitrum International AB develops, manufactures, and sells pharmaceutical products and drugs. It offers patients and partners an international network specializing in the development, marketing and distribution of orphan drugs. The company is headquartered in Stockholm, Sweden.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
MipSalus ApS
 MipSalus ApS Miscellaneous Commercial ServicesCommercial Services MipSalus ApS is a Danish company that conducts research and experimental development in the field of natural sciences and engineering.
1
| Private Company | Miscellaneous Commercial Services | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Bo Jesper Hansen via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Cephalon, Inc.
 Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Comptroller/Controller/Auditor | |
Scios, Inc.
 Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Investor Relations Contact | |
| INVESTOR AB | Financial Conglomerates | Chief Executive Officer Corporate Officer/Principal Director of Finance/CFO | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
CoTherix, Inc.
 CoTherix, Inc. Pharmaceuticals: MajorHealth Technology CoTherix, Inc. develops therapeutic products. Its ventavis product is a nebulizer delivered therapy for pulmonary artery hypertension, which restricts blood flow to the lungs. CoTherix markets its products in the US, Europe, and Australia. The company was founded in February, 2000 by Donald J. Santel and Gerard Turino and is located in Brisbane, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Founder General Counsel Compliance Officer | |
| AEROCRINE AB | Electronic Equipment/Instruments | Director/Board Member Founder | |
| ANTHERA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member General Counsel Director of Finance/CFO | |
| ROVSING A/S | Information Technology Services | Director/Board Member Chairman Director/Board Member | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | General Counsel Corporate Officer/Principal Corporate Officer/Principal | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Chief Executive Officer | |
| Karolinska Institutet | College/University | Director/Board Member Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Corporate Officer/Principal Corporate Officer/Principal Consultant / Advisor | |
| OREXO AB | Pharmaceuticals: Major | Chief Executive Officer Chairman Chairman | |
| University of California, Berkeley | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree | |
| University of Maryland | College/University | Undergraduate Degree Undergraduate Degree | |
| Copenhagen Business School | College/University | Graduate Degree Graduate Degree Masters Business Admin Graduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Stockholm School of Economics | College/University | Graduate Degree Masters Business Admin Graduate Degree Graduate Degree Masters Business Admin Director/Board Member | |
| University of Uppsala | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree | |
Biolipox AB
 Biolipox AB Pharmaceuticals: MajorHealth Technology Biolipox AB develops and manufactures pharmaceuticals products. The company engages in the research and development of pharmaceuticals for the treatment of respiratory and other inflammatory diseases such as asthma, chronic obstructive pulmonary disease, rhinitis, pain, and arthritis. It was founded in June 2000 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
Horizon Therapeutics Switzerland GmbH
 Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer Corporate Officer/Principal | |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| Technical University of Denmark | College/University | Corporate Officer/Principal Graduate Degree Doctorate Degree | |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer Corporate Officer/Principal | |
| VIVESTO AB | Pharmaceuticals: Generic | Director/Board Member Chairman Chief Executive Officer | |
| Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member Chairman Chief Executive Officer | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member Chief Executive Officer | |
| SAGIMET BIOSCIENCES INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member Chairman | |
| RAPTOR PHARMACEUTICAL CORP | Pharmaceuticals: Major | Director/Board Member Compliance Officer Director of Finance/CFO | |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer Chairman | |
| EGETIS THERAPEUTICS AB | Pharmaceuticals: Major | Chairman Director/Board Member Investor Relations Contact | |
Bankinvest Biomedical Venture
 Bankinvest Biomedical Venture Investment ManagersFinance Bankinvest Biomedical Venture provides investment services. The company was founded in 1998 and is headquartered in Copenhagen, Denmark. | Investment Managers | Corporate Officer/Principal Corporate Officer/Principal | |
Contera Pharma ApS
 Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member | |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member Chairman Director/Board Member Chief Executive Officer | |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman | |
KDev Investments AB
 KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Biotechnology | Director/Board Member Director/Board Member Chairman | |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| OBSEVA SA | Pharmaceuticals: Major | Director/Board Member Chairman | |
Rigontec GmbH
 Rigontec GmbH Pharmaceuticals: MajorHealth Technology Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
| VIELA BIO, INC. | Biotechnology | President Director/Board Member | |
| GALECTO, INC. | Pharmaceuticals: Major | Chairman Director/Board Member |
Statistics
International
| Sweden | 20 |
| United States | 13 |
| Denmark | 10 |
| Switzerland | 4 |
| Germany | 4 |
Sectoral
| Health Technology | 34 |
| Consumer Services | 9 |
| Commercial Services | 5 |
| Finance | 4 |
| Electronic Technology | 2 |
Operational
| Director/Board Member | 781 |
| Corporate Officer/Principal | 219 |
| Chairman | 213 |
| Independent Dir/Board Member | 178 |
| Chief Executive Officer | 144 |
Most connected contacts
- Stock Market
- Insiders
- Bo Jesper Hansen
- Company connections
